TY - JOUR
T1 - Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells
AU - Okazaki, Shogo
AU - Nakatani, Fumi
AU - Masuko, Kazue
AU - Tsuchihashi, Kenji
AU - Ueda, Shiho
AU - Masuko, Takashi
AU - Saya, Hideyuki
AU - Nagano, Osamu
N1 - Publisher Copyright:
© 2016 The Authors.
PY - 2016/1/29
Y1 - 2016/1/29
N2 - The use of monoclonal antibodies (mAbs) for cancer therapy is one of the most important strategies for current cancer treatment. The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, which regulates cancer cell proliferation, survival, and migration, is a major molecular target for antibody-based therapy. ErbB4/HER4, which contains a ligand-binding extracellular region, is activated by several ligands, including neuregulins (NRGs), heparin-binding EGF-like growth factor, betacellulin and epiregulin. Although there are clinically approved antibodies for ErbB1 and ErbB2, there are no available therapeutic mAbs for ErbB4, and it is not known whether ErbB4 is a useful target for antibody-based cancer therapy. In this study, we developed an anti-ErbB4 mAb (clone P6-1) that suppresses NRG-dependent activation of ErbB4 and examined its effect on breast cancer cell proliferation in the extracellular matrix.
AB - The use of monoclonal antibodies (mAbs) for cancer therapy is one of the most important strategies for current cancer treatment. The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, which regulates cancer cell proliferation, survival, and migration, is a major molecular target for antibody-based therapy. ErbB4/HER4, which contains a ligand-binding extracellular region, is activated by several ligands, including neuregulins (NRGs), heparin-binding EGF-like growth factor, betacellulin and epiregulin. Although there are clinically approved antibodies for ErbB1 and ErbB2, there are no available therapeutic mAbs for ErbB4, and it is not known whether ErbB4 is a useful target for antibody-based cancer therapy. In this study, we developed an anti-ErbB4 mAb (clone P6-1) that suppresses NRG-dependent activation of ErbB4 and examined its effect on breast cancer cell proliferation in the extracellular matrix.
KW - Breast cancer
KW - ErbB4
KW - Neuregulin
KW - Neutralizing antibody
KW - Three-dimensional culture
UR - http://www.scopus.com/inward/record.url?scp=84956591552&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84956591552&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2016.01.045
DO - 10.1016/j.bbrc.2016.01.045
M3 - Article
C2 - 26780728
AN - SCOPUS:84956591552
SN - 0006-291X
VL - 470
SP - 239
EP - 244
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 1
ER -
